Pharmaceutical intermediates
AVACOPAN Intermediates
5 pharmaceutical intermediates for AVACOPAN. Indication: Antineutrophil cytoplasmic antibody-associated vasculitis; Wegener's granulomatosis; microscopic polyangiitis.
About AVACOPAN
- Originator
- Chemocentryx Inc
- Indication
- Antineutrophil cytoplasmic antibody-associated vasculitis; Wegener's granulomatosis; microscopic polyangiitis
- Approved Date
- 10/07/2021
- NCE Patent
- 10/07/2026
- DS/DP
- 12/21/2029
Available intermediates
5 intermediates currently listed for AVACOPAN. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| Ethyl (2R,3S)-2-(4-(cyclopentylamino)phenyl)piperidine-3-carboxylate bis((2R,3R)-2,3-bis((4-methylbenzoyl)oxy)succinate) | 1893415-79-6 | / | / |
| (2R,3S)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)piperidine-3-carboxylic acid | 1346623-11-7 | / | / |
| tert-butyl 3-(4-nitrophenyl)-3-oxopropanoate | 142550-25-2 | / | / |
| Ethyl 4-nitrobenzoylacetate | 838-57-3 | / | / |
| Butanedioic acid, 2,3-bis[(4-methylbenzoyl)oxy]-, (2R,3R)-, compd. with ethyl (2R,3S)-2-[4-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-3-piperidinecarboxylate (1:1) | 1357259-88-1 | / | / |
Building toward AVACOPAN?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →